COSM

MKT CAP:$11M

Cosmos Health Inc.

Market Cap

$11M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$0.36-$0.16 (-30.68%)

Apr 23, 2026

Company Details

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices...

CEO

Grigorios Siokas

IPO Date

Jul 23, 2010

Website

www.cosmosholdingsinc.com

Key Metrics TTM

Revenue

$65M

+19.9% YoY

Net Income

-$19M

EPS (Diluted)

-$0.63

Free Cash Flow

-$10M

Revenue / Share

$2.15

Gross Margin

12.1%

Operating Margin

-25.3%

Net Margin

-29.3%

FCF Margin

-15.6%

P/S

0.2x

P/E

—

Earnings Reports

FY 2025

Apr 15, 2026

NEW

$65M+19.9%EPS -$0.63

Q4 2025

Apr 15, 2026

NEW

$20M+38.5%EPS -$0.33

Q3 2025

Nov 14, 2025

$17M+37.9%EPS -$0.17

Q2 2025

Aug 15, 2025

$15M+11.7%EPS -$0.10

Q1 2025

May 15, 2025

$14M-6.0%EPS -$0.03

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$13M	$2M	$242.3K
Q2 22	$13M	$2M	-$74.4K
Q3 22	$12M	$2M	-$344.1K
Q4 22	$12M	$435.3K	-$7M
Q1 23	$12M	$957.1K	-$3M
Q2 23	$12M	$946.8K	-$3M
Q3 23	$13M	$1M	-$3M
Q4 23	$16M	$1M	-$14M
Q1 24	$15M	$1M	-$2M
Q2 24	$13M	$767.2K	-$3M
Q3 24	$12M	$1M	-$2M
Q4 24	$14M	$1M	-$9M
Q1 25	$14M	$2M	-$833.1K
Q2 25	$15M	$1M	-$3M
Q3 25	$17M	$3M	-$2M
Q4 25	$20M	$2M	-$11M

Valuation

Quarter	P/S	P/E
Q1 22	0.0x	—
Q2 22	0.1x	—
Q3 22	0.0x	—
Q4 22	0.9x	—
Q1 23	0.8x	—
Q2 23	0.8x	—
Q3 23	0.3x	—
Q4 23	0.4x	—
Q1 24	0.2x	—
Q2 24	0.4x	—
Q3 24	0.3x	—
Q4 24	0.2x	—
Q1 25	0.2x	—
Q2 25	0.2x	—
Q3 25	0.5x	—
Q4 25	0.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$2M	-$2M
Q2 22	-$686.4K	-$1M
Q3 22	-$2M	-$2M
Q4 22	-$10M	-$10M
Q1 23	-$6M	-$6M
Q2 23	-$6M	-$9M
Q3 23	-$5M	-$7M
Q4 23	$951.7K	-$3M
Q1 24	-$3M	-$3M
Q2 24	-$1M	-$1M
Q3 24	$739.8K	$511.0K
Q4 24	-$4M	-$5M
Q1 25	-$186.3K	-$200.1K
Q2 25	-$1M	-$1M
Q3 25	-$4M	-$4M
Q4 25	-$5M	-$5M

Capital Expenditures

Quarter	CapEx
Q1 22	$4.4K
Q2 22	$347.5K
Q3 22	$0
Q4 22	$34.1K
Q1 23	$26.0K
Q2 23	$3M
Q3 23	$2M
Q4 23	$4M
Q1 24	$82.7K
Q2 24	$34.2K
Q3 24	$228.8K
Q4 24	$921.6K
Q1 25	$13.8K
Q2 25	$118.6K
Q3 25	$12.7K
Q4 25	$103.9K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+12.5%	-3.9%
Q2 22	-11.0%	-18.1%
Q3 22	-11.6%	-14.8%
Q4 22	-25.5%	+15.9%
Q1 23	-5.5%	+16.9%
Q2 23	-6.4%	+12.5%
Q3 23	+6.7%	+28.2%
Q4 23	+31.4%	+52.1%
Q1 24	+18.1%	+9.5%
Q2 24	+6.8%	+5.1%
Q3 24	-3.2%	-7.5%
Q4 24	-10.2%	-21.2%
Q1 25	-6.0%	-11.4%
Q2 25	+11.7%	+10.7%
Q3 25	+37.9%	+29.2%
Q4 25	+38.5%	+33.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	0.0%
Q2 22	$24.1K	0.2%
Q3 22	$3.1K	0.0%
Q4 22	-$2.8K	-0.0%
Q1 23	$0	0.0%
Q2 23	$104.9K	0.8%
Q3 23	$109.6K	0.9%
Q4 23	$363.4K	2.3%
Q1 24	$340.2K	2.3%
Q2 24	$340.2K	2.6%
Q3 24	$422.8K	3.4%
Q4 24	$586.5K	4.1%
Q1 25	$556.6K	4.1%
Q2 25	$603.0K	4.1%
Q3 25	$0	0.0%
Q4 25	$582.0K	3.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	—	$1M	$146.9K
Q2 22	—	$2M	$245.4K
Q3 22	—	$2M	$104.0K
Q4 22	—	$8M	$133.7K
Q1 23	—	$3M	$467.3K
Q2 23	—	$3M	$318.1K
Q3 23	—	$4M	$157.4K
Q4 23	—	$14M	$261.9K
Q1 24	—	$3M	$173.6K
Q2 24	—	$3M	$110.8K
Q3 24	—	$3M	$41.8K
Q4 24	—	$9M	$28.7K
Q1 25	$15.6K	$3M	$28.2K
Q2 25	$74.6K	$3M	$21.7K
Q3 25	$18.3K	$2M	$64.8K
Q4 25	$410.8K	$8M	$35.6K

Revenue Segments

Quarter	Nutraceuticals and Pharmaceuticals	Pharma manufacturing	Wholesale
Q3 25	$2M	$412.6K	$15M
Q4 25	—	$206.9K	$19M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$1M	$12.6K	$1M
Q2 22	$562.3K	$10.3K	$572.7K
Q3 22	$312.4K	$10.0K	$322.4K
Q4 22	$21M	$14.9K	$21M
Q1 23	$12M	$16.4K	$12M
Q2 23	$2M	$19.2K	$2M
Q3 23	$2M	$17.5K	$2M
Q4 23	$4M	$20.1K	$4M
Q1 24	$865.1K	$21.3K	$886.4K
Q2 24	$343.5K	$21.5K	$365.0K
Q3 24	$3M	$22.8K	$3M
Q4 24	$315.1K	$21.1K	$336.3K
Q1 25	$742.9K	$25.3K	$768.2K
Q2 25	$655.5K	$30.3K	$685.8K
Q3 25	$889.4K	$33.2K	$922.6K
Q4 25	$715.7K	$46.2K	$761.8K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	710K	+3.6%	+18.1%
Q2 22	871K	+22.7%	+35.2%
Q3 22	1M	+18.5%	+50.6%
Q4 22	2M	+86.8%	+181.3%
Q1 23	11M	+450.5%	+1394.6%
Q2 23	11M	+1.9%	+1141.9%
Q3 23	13M	+16.3%	+1119.2%
Q4 23	12M	-4.9%	+520.7%
Q1 24	17M	+40.8%	+58.8%
Q2 24	18M	+5.8%	+64.8%
Q3 24	18M	+3.3%	+46.3%
Q4 24	19M	+4.0%	+60.0%
Q1 25	24M	+25.1%	+42.1%
Q2 25	29M	+20.1%	+61.2%
Q3 25	31M	+6.5%	+66.3%
Q4 25	30M	-1.1%	+58.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$137.6K	95
Q2 22	$139.0K	95
Q3 22	$126.5K	95
Q4 22	$118.1K	102
Q1 23	$121.1K	102
Q2 23	$121.2K	102
Q3 23	$125.7K	102
Q4 23	$100.3K	158
Q1 24	$92.3K	158
Q2 24	$83.6K	158
Q3 24	$78.6K	158
Q4 24	$95.5K	149
Q1 25	$92.0K	149
Q2 25	$99.0K	149
Q3 25	$114.8K	149
Q4 25	$120.9K	163

Revenue / Employee